title: The neuroprotective agent DP-b99 does not interact with s-warfarin in vivo despite significant CYP2C9 inhibition in vitro.
authors.affiliation: D-Pharm Ltd., Rehovot, Israel. grosenberg@dpharm.com
authors.forename: Gilad
authors.initials: G
authors.lastname: Rosenberg
authors.forename: Linda S
authors.initials: LS
authors.lastname: Marshall
authors.forename: Yoseph
authors.initials: Y
authors.lastname: Caraco
mesh_terms: D000328:Adult; D000925:Anticoagulants / Q000008:administration & dosage* / Q000494:pharmacology; D001189:Aryl Hydrocarbon Hydroxylases / Q000037:antagonists & inhibitors* / Q000235:genetics; D018592:Cross-Over Studies; D065729:Cytochrome P-450 CYP2C9; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004347:Drug Interactions; D004533:Egtazic Acid / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology; D005838:Genotype; D006801:Humans; D008297:Male; D018696:Neuroprotective Agents / Q000008:administration & dosage* / Q000494:pharmacology; D014859:Warfarin / Q000008:administration & dosage* / Q000494:pharmacology; D055815:Young Adult
chemical_list: D000925:Anticoagulants; C428064:DP-b99; D018696:Neuroprotective Agents; D004533:Egtazic Acid; D014859:Warfarin; C450260:CYP2C9 protein, human; D065729:Cytochrome P-450 CYP2C9; D001189:Aryl Hydrocarbon Hydroxylases